Promedior is a product-focused biopharmaceutical company developing novel
therapeutics for the treatment of fibrotic diseases and tissue remodeling.
Fibrosis is a key component of multiple diseases affecting all tissues and organ
systems and is a leading cause of morbidity and mortality for millions of people
worldwide. Promedior has developed a novel platform to treat fibrotic
diseases which focuses on targeting the specific cell populations, namely
monocytes and macrophages, that orchestrate fibrosis and tissue remodeling.
This new paradigm for treating fibrotic diseases is upstream and dominant to
traditional approaches and takes advantage of universal biology common to all
tissues to promote healing without scarring.
Promedior’s lead product, PRM-151, is a recombinant form of human Serum
Amyloid P (rhSAP) with broadly active anti-fibrotic activity. PRM-151 has
demonstrated an outstanding safety profile and robust preclinical efficacy in
multiple models of fibrotic disease and tissue remodeling, including Idiopathic
Pulmonary Fibrosis and Asthma, as well as ophthalmic, kidney, heart, and liver
disease. Promedior initiated a Phase 1 clinical trial of PRM-151 in July
2009. The Phase 1 dose escalation study is designed to evaluate the
safety, tolerability, pharmacokinetics and exploratory pharmacodynamics of
ascending single intravenous doses of PRM-151. Promedior intends to
initially pursue ophthalmic indications associated with aberrant tissue
remodeling, followed by clinical studies for chronic Pulmonary and Renal
indications using systemic administration.
